A Phase I Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Lefitolimod (Primary) ; Ipilimumab
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 13 Jul 2016 According to a Mologen media release, patient recruitment in this trial is expected to be completed at the beginning of 2018.
- 13 Jul 2016 According to a Mologen media release, first patient has been enrolled in this trial.
- 11 May 2016 Planned primary completion date changed from 1 Aug 2019 to 1 May 2019.